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INTRODUCTION 
Over active bladder [OAB] is becoming an internationally “hot topic.” 
The tremendous number of patients with this problem is just now becoming 
recognized, and the potential economic impact is staggering. World wide, OAB 
is known to affect 50-100 million people. The condition is probably under 
reported and under treated, since patients have not become totally aware that 
they are suffering from OAB. More over the patients do not recognize that their 
condition is not normal and needs treatment.1  
In the United States alone, there are an estimated 32 or 33 million 
people affected by OAB. It costs an estimated $26 billion a year in the United 
States to manage loss of bladder control. With continued ageing of the 
populations in all developed countries, the problems associated with bladder 
control will certainly continue to increase2. 
The industry and medical fraternity there fore can make a substantial 
contribution to the quality of life [QoL] of these patients by spreading 
awareness and education of OAB, thanks to the latest advances in the disease 
understanding and therapy options to treat this condition. 
 In US one in eleven incontinent patients suffers from OAB. 
 Approximately 55% of individuals with OAB are women and 
45% are men. 
 2 
 The prevalence of the condition is reported to be around 16 to 
22% and it  increases with advancing age. 
 Women with urinary problems during childhood are more likely 
to develop OAB as adults. The connection between childhood 
urinary symptoms and adult symptoms of OAB raises the 
possibility of early identification of a population at risk for adult 
OAB symptoms. 
 The prevalence of OAB is 29.9% in Asian men.  OAB is more 
common in professional workers [43%], the high-income group and 
urban dwellers [64%].  
 With increasing age the incidence of OAB increases, i.e., the 
prevalence is 53% in men aged >70 years.  
 Among patients who seek help,   30%, do not receive assessment and 
approximately 80% are not treated. 3, 4, 5 
Over active bladder is a syndrome characterized by collection of   
symptoms composed of urinary frequency, urgency, urge incontinence and 
nocturia. The current International Continence Society (ICS) definition states 
that OAB syndrome is characterized by 
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1. Urgency  [a sudden desire to pass urine which is hard to delay] 
2.  Urge incontinence [involuntary leakage of urine accompanied or 
preceded by urgency], usually with 
3. Increased frequency, and 
4. Nocturia 
It is further characterized by reduction in volume voided per void and 
thus decreased bladder capacity, in the absence of pathological or metabolic 
factors that would explain these symptoms. 6, 7 
      Such symptoms are known to be highly prevalent with in the general 
population, contributing to a significant impairment in Health Related Quality 
of Life [HRQoL].   
 It is a distressing condition that can diminish people′s self esteem and 
quality of life. Frequently, sufferers do not seek medical care because they 
believe that their symptoms are part of the normal aging process. While OAB is 
idiopathic, in most cases it is described as a pathophysiological process and not 
merely a part of normal aging. 
           The anti muscarinic drugs have become the gold standard treatment for 
OAB. The two antimuscarinic agents used most often in clinical practice 
include oxybutynin and tolterodine. Ideally with any drug it is desirable to have 
it work selectively on the target of interest (e.g. the M3 muscarinic receptor), 
 4 
because this could, in theory, minimize adverse effects. However because of 
the extremely high sequence homology of the five identified muscarinic 
receptors. It has been difficult for medicinal chemists to develop selective 
compounds at these receptors. Neither oxybutynin nor tolterodine has much 
selective for the various subtypes of the muscarinic receptors and each has 
about the same affinity for the M3 subtypes. 8, 9, 10 
Oxybutynin is selective for M1 and M3 receptors subtypes, while 
tolterodine is a non–selective muscarinic antagonist. The non-selective anti 
muscarinics are associated with myriad of side effects. The most commonly 
reported adverse events with these agents include dry mouth, constipation, 
dizziness, headache, dry eyes and drowsiness. Aside from the afore mentioned 
tolerability profile, the use of these agents is also contraindicated in patients 
with obstructive uropathy, glaucoma, urinary retention and a number of 
gastrointestinal complaints.11,12.13 
These drugs have limited effectiveness, as well as significant side 
effects, which lead the patient often to discontinue the therapy. 
Hence introduction of a more bladder specific muscarinic antagonists 
with fewer side effects and contraindications is needed. 
Solifenacin is a highly potent and bladder selective muscarinic (M3) 
receptor antagonist developed for the treatment of OAB with fewer side effects. 
[M3 subtype receptor is responsible for normal and involuntary bladder 
contraction.]14, 15 
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Solifenacin succinate is a once-daily oral antimuscarinic agent that 
shows apparent functional selectivity for bladder over other organs.  
 Solifenacin has been shown to be effective in reducing the symptoms of 
OAB in reducing incontinence episodes per day, decreasing the number of 
micturition in 24 hours and increasing mean voided volume. In addition 
significant reduction in urinary urgency was also reported. 
This study was taken up to assess the efficacy and tolerability of 
solifenacin given once daily compared with the commonly used drug 
tolterodine given twice daily in patients with OAB. 
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REVIEW OF LITERATURE 
Over active bladder is a new terminology defined in terms of either 
urodynamic findings or symptoms. It is a chronic disease that is usually caused 
by involuntary contractions of the detrusor muscle during bladder filling. The 
urodynamic definition of OAB approximates that of International Continence 
Society (ICS) term. 
The bladder is a four – sided pyramid like structure. Its capacity is about 
200 – 300 CC. When it is full it is ovoid in shape. The bladder wall is made of 
longitudinal and circular muscles called the detrusor16. 
The bladder performs several important functions. It must store an 
adequate volume of urine. The proper understanding of voiding and continence 
requires some working knowledge of the contractile properties of the smooth 
and striated muscles of the bladder. The lower urinary tract has two main 
functions, storage and periodic elimination of urine. These functions are 
regulated by unique biomechanics of bladder and urethral muscle as well as 
complex neural control system located in the brain and spinal cord.17  
As a result of extensive research the complex neural circuit regulating 
normal function of the lower urinary tract is now better understood. A quick 
review of the normal neurophysiologic control of lower urinary tract function 
makes it easier to understand the rationale for pharmacological approach in the 
management OAB. 
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The smooth muscle lining of the bladder neck and urethra form the 
internal sphincter, which is surrounded by striated muscles called rhabdo 
sphincter. Together, the striated muscle fibers surrounding the urethra and 
rhabdo sphincter constitute the external urethral sphincter (EUS). 
Neurophysiology of urinary bladder18 - 20 
Para sympathetic nerves innervate the detrusor where as the smooth 
muscles of the bladder neck and urethra (the internal sphincter) are innervated 
by sympathetic nerves. The striated muscles of the EUS receive their primary 
innervations from somatic nerves. 
 
 
 
 
 
 
Fig.1 : Sympathetic and para sympathetic pathway 
The parasympathetic pathway of the detrusor comes as the pelvic 
nerve from the nucleus in the intermediolateral column of segments S2 – S4 
and synapse in the pelvic ganglia, as well as in small ganglia on the bladder 
wall, releasing acetylcholine (Ach). The postganglionic axons continue for a 
short distance in the pelvic nerve and terminate in the detrusor layer where they 
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release Ach to the smooth muscle fibers, with consequent contractions of the 
bladder. Effect of Ach is mediated by muscarinic receptors in detrusor cells. 
Although M2 is most abundant in detrusor cells, the M3 sub- type is the major 
receptor mediating stimulation of detrusor contractions. 
In addition to this, some postsynaptic parasympathetic neurons exert a 
relaxation effect on urethral smooth muscles, most likely via nitric oxide (NO) 
Fig.1. Thus when the bladder contracts during micturition phase, the internal 
urethral sphincter relaxes. 
 
 
 
 
 
 
Fig.2 : Reflex Pathway 
Sympathetic nerves stimulate smooth muscle contraction in the urethra 
and bladder neck and cause relaxation of the detrusor. Sympathetic neurons in 
the intermediolateral column of segments T10 – L2 synapse with 
postganglionic neurons in the inferior mesenteric ganglia. Postganglionic axons 
travel in the hypo gastric nerve and release nor epinephrine (NE) at their 
terminals in the urethra, the bladder neck, and the bladder body. NE stimulates 
contraction of urethral and bladder neck smooth muscles via α1–adrenoceptors 
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and causes relaxation of detrusor via β2 – adrenoceptors and β3 – 
adrenoceptors, the latter being most predominant. 
Somatic nerves provide excitatory innervations to the striated muscles 
of the EUS and pelvic floor. The efferent motor neurons are located in Onuff’s 
nucleus in spinal cord segments S2 – S4. The motor neuron axons are carried in 
the pudendal nerve and release Ach at their terminals. Ach acts on nicotinic 
receptors in the striated muscles, inducing muscle contraction to maintain 
closure of the EUS. 
Decades of experiments and clinical studies have shown that normal 
coordination of storage and voiding function requires integration from 
supraspinal input. Besides as yet undetermined, the regions in the brainstem 
that act as components of the supraspinal – spinal – lower urinary tract pathway 
are the laterodorsal tegmental nucleus, known as the pontine micturitition 
center (PMC). 
Ventrolateral to the PMC is a region referred to as the pontine storage 
center (PSC). The PMC and PSC are the final integrative centers, receiving and 
integrating input from afferent spinal cord nerves and more rostral brain 
regions and controlling the lower urinary tract. Neurons in the PSC project 
directly to the motor neurons in Onuff’s nucleus and stimulation of PSC 
neurons cause EUS contractions. Neurons in the PMC project to the sacral 
parasympathetic nucleus, and stimulation of PMC neurons results in bladder 
contractions as well as relaxation of the internal urethral sphincter and EUS 
(Fig.2). 
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Multiple reflex pathways operate between the CNS and the lower 
urinary tract. At the simplest level, the central pathways operate as on / off 
switching. These circuit switches are timed precisely so that, when urethral 
smooth muscle is being stimulated by the hypogastric nerve to contract the 
bladder detrusor is not receiving stimulatory input from the pelvic nerve. 
CAUSES OF OAB 21 
1. Idiopathic – Majority of cases do not have a demonstrable cause. 
2. Neurological injuries – spinal cord injury or cerebro vascular accident. 
3. Neurological disease – Multiple sclerosis, Dementia, Parkinson’s 
disease, Medullary lesions. 
4. Non – neurological causes – urinary tract infection, carcinoma bladder, 
Bladder calculi, Bladder inflammation, or Bladder out Let obstruction 
(BOO) 
5. Drug therapy – Diuretics can lead to symptoms of urge incontinence. 
This is due to increased filling of the bladder, stimulating the detrusor. 
Drugs used in urinary retention can also lead to increased contractions of 
detrusor leading to OAB. 
When the bladder fills, detrusor activity may be either normal or 
increased (over activity). The normal bladder may also be termed as “stable” in 
comparison to OAB which is termed as “unstable”. In normal function; 
detrusor relaxes and stretches to allow the bladder to increase the volume 
without any change in pressure. This low – pressure system is important for 
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two principal reasons. Firstly, it allows efficient transport of urine through the 
ureters. Second, it is an essential factor in maintaining continence. 
Detrusor Instability (DI) 
It occurs during the filling phase. These are involuntary detrusor 
contractions that the patient cannot suppress. These contractions may be 
spontaneous or else may only occur on provocation. The unstable detrusor may 
be asymptomatic and its presence does not necessarily imply a neurological 
disorder. This is the commonest form of detrusor over activity. 
DI can manifest in different patterns: 
 Spontaneous DI – The instability has no particular trigger. 
 Provoked DI – Instability is triggered by a certain factor, and is 
categorized by the provoking factor. The commonest are change  in 
position, for e.g. rising from sitting or lying to standing and 
coughing. 
 Hand – washing or putting hands into cold water. 
 Latchkey incontinence where a patient wishing to pass urine reaches 
the front door but before they can turn the key they have extreme 
urgency and leak 
 Telephone urgency (where telephone conversation can lead to 
urgency) 
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Normal patients with over active bladder can be divided mainly into two 
broad groups a) Idiopathic DI. b) DI and Bladder outlet obstruction. 
a. Idiopathic DI. 
Idiopathic DI, with or without urge incontinence, is a common 
urological problem. It is more prevalent in females and men are also not 
excluded from this. The incidence increases significantly with age. 
b. DI and Bladder outlet obstruction 
DI may or may not occur in the presence of bladder outlet obstruction. 
In majority of cases this is due to benign prostatic obstruction (BPO) secondary 
to benign prostatic enlargement (BPE). DI occurs in 50 – 75% of men with 
bladder outlet obstruction. 
Detrusor Hyper reflexia 
Detrusor hyper reflexia is defined as bladder over activity due to 
disturbance of the nervous control mechanisms. There are a number of 
neurological conditions which commonly lead to lower urinary tract 
dysfunction. These conditions may be congenital, for example 
meningomyelocele or sacral agenesis or else acquired including multiple 
sclerosis, cerebrovascular accidents, spinal cord trauma and parkinsons disease. 
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Urge Incontinence 
Urinary urgency and urge incontinence are two of the common 
symptoms that characterize OAB syndrome22. Other symptoms include urinary 
frequency (more than 8 micturitions in 24 hours) and nocturia. 
 Urge incontinence is an abrupt and intense urge to urinate that cannot be 
suppressed, followed by an uncontrollable loss of urine. Some people 
experience the abrupt and intense urge to urinate but are still able to remain 
continent. People with urge incontinence usually have little time to get to the 
bath room before they have an accident. 
Urge incontinence is reported in around 20% of men and 40% of women 
with over active bladder symptoms, and is the most bothersome & upsetting 
symptom of an over active bladder23. 
Urge incontinence is the most common type of persistent incontinence 
in older people and often has no clear cause. Urge incontinence in older people 
may be caused by a combination of over activity of the muscles in the bladder 
along with poor squeezing ability of those muscles. Chronic over activity of the 
bladder is common in older people and cause abrupt and intense urge to urinate 
as well as frequent urination during the day and night. 
MANAGEMENT OF OVER ACTIVE BLADDER 
 Treatment of detrusor over activity can be divided into  
I. Non pharmacological and 
II. Pharmacological aspects 
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I Non pharmacological 
A. Conservative  
B. Electrical stimulation  
C. Surgical management 
II Pharmacological 
 Anti – cholinergic agents  
 Calcium antagonists  
 Potassium channel openers 
 Prostaglandin inhibitors 
 Adrenergic drugs 
 Tricyclic anti depressants 
I. Non – Pharmacological 
A. CONSERVATIVE 24 
A- 1. Behavioral therapy 
Advice on fluid intake, this includes the volume, timing and the type of 
fluid taken. Patients should be advised 
- Not to drink before going out  
- Not to drink prior to bed time or during night. 
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- To maintain an adequate fluid in take i.e. one to two liters. 
- To avoid fluids which precipitate symptoms, like caffeine and 
alcohol. 
A – 2. Bladder training  
Bladder training, behavioral therapy, behavioral modifications are the 
terms used interchangeably in this. 
- Patient education about lower urinary tract function 
- Which includes instituting intervals of timed voiding and gradually 
increasing these intervals 
A – 3. Pelvic floor exercises (PFE) 
The patients are taught to do “quick flicks” of the pelvic floor 
musculature, to inhibit the micturition reflex.  
A – 4. Bio feed back 
 It is a technique that provides visual and or auditory signals to an 
individual with respect to his or her performance of a physiologic process, in 
this case pelvic floor muscle contraction, EMG or vaginal pressure 
measurement are generally used. 
B. ELECTRICAL STIMULATION 
Neuro stimulation of the pudendal nerves or sacral roots has been shown 
to inhibit detrusor contractions presumably by the recruitment of the inhibitory 
 16 
neural pathways. To date, there are still no clinical predictors for the out come 
of neuro stimulation.25 
C. SURGICAL MANAGEMENT 
This is reserved for those patients who have failed conservative 
treatment. The various procedures described are 
 Cystoplasty: At present it is the most effective procedure for the 
symptomatic relief of over active bladder. 
 Detrusor myomectomy 
It is considered to be inferior to cystoplasty, it involves removal of a 
segment of detrusor muscle. 
II. Pharmacological  
By pharmacological as well as molecular cloning techniques muscarinic 
receptors have been divided into five subtypes.26 
M1 -  In brain – cortex, Hippo campus, glands, sympathetic ganglia 
M2 - In heart, hind brain, smooth muscles 
M3 - In smooth muscles, glands, brain  
M4 - In basal fore brain, striatum 
M5 - Substantia nigra 
The drugs for over active bladder are: 
    1. Anti-cholinergic 
a. Oxybutynin chloride  
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b.  Propiverine 
c. Dicyclomine hydrochloride 
d. Flavoxate hydro chloride 
e.  Propanthaline bromide  
f.  Trospium chloride  
g.  Darifenacin  
h.  Tolterodine chloride 
i.  Solifenacin. 
2.  Calcium antagonists 
a.Terodiline 
3. Potassium channel openers 
4.  Prostaglandin inhibitors 
5.  β - Adrenergic Agonists 
6.  α - Adrenergic Antagonists 
7. Tri cyclic anti – depressants 
1.a. OXYBUTYNIN CHLORIDE  
It is approved for use in OAB since 1972 and it remained the comer 
stone of OAB therapy for over 20 years. It is selective for M1 and M3 
muscarinic receptors. It has a direct anti spasmodic and has some local 
anesthetic effect in urinary bladder. 
It under goes extensive first pass metabolism to N-des ethyl oxybutynin 
(DEO) an active anti cholinergic metabolite that has properties six fold higher 
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than the parent compound. In humans, it has higher affinity for parotid gland 
than bladder27. The drug was developed originally for gastro intestinal hyper 
motility disorders. Its direct smooth muscle relaxant effects are 500 times 
weaker than its anti – muscarinic effects28. DEO is responsible for the majority 
of the adverse effects of oxybutynin. Alternate routes of administration are by 
intravesical, skin patches, or rectal routes. High incidence of side effects 
particularly related to salivary gland secretion is often significant enough to 
cause patients to discontinue taking the medication. 
1.b. PROPIVERINE  
It is a tertiary amine similar to oxybutynin. It has direct muscle relaxant 
properties and local anaesthetic activity. The urodynamic effect is similar to 
oxybutynin. The incidence of dryness of mouth is lower than oxybutynin with 
propiverine. 
1.c. DICYCLOMINE HYDROCHLORIDE  
It has a direct relaxant effect on smooth muscles in addition to anti 
muscarinic action. Dicyclomine is not widely used in the treatment of OAB. 
1.d. FLAVOXATE HYDROCHLORIDE  
It has a weak anti cholinergic effect, moderate calcium antagonist 
activity, local anaesthetic properties and ability to inhibit phosphodiesterase. It 
has no effect on detrusor hyper reflexia. 
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1.e. PROBANTHALINE BROMIDE  
It is a non – selective muscarinic antagonist. High doses produce 
symptoms of ganglionic blockade. Toxic doses block the skeletal 
neuromuscular function. 
1.f. TROSPIUM CHLORIDE  
It has anti muscarinic action having higher specificity towards M3 
receptor in the bladder. Because this drug does not undergo hepatic metabolism 
by cytochrome P-450 system at therapeutic levels, 80% of the drug is execrated 
unchanged in the urine. Additionally, its safety profile for reducing CNS 
effects is promising due to the hydrophilic design, which minimizes passage of 
the drug through the blood brain barrier. 29, 30 
1.g. DARIFENACIN 
It is a selective M3 receptor antagonist with selectivity for urinary 
bladder over the salivary glands. It has adverse effects like dry mouth, 
constipation, dizziness and somnolence. 10mg dose of darifenacin showed 
urodynamic improvements in patients with OAB, with significant reduction in 
salivary flow. 2.5 mg dose not have any effect on salivation, but this dose is not 
effective for bladder. 31, 32 
2. CALCIUM CHANNEL BLOCKERS: - TERODILINE  33  
The role of calcium as a messenger in linking extracellular stimuli to the 
intracellular environment is well established including its involvement in 
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excitation – contraction coupling in striated, cardiac and smooth muscles. The 
dependence of contractile activity on changes in cytosolic calcium varies from 
tissues to tissue, as do the characteristics of the calcium channels involved. It 
has both calcium antagonist and anti cholinergic properties. At low 
concentration, it has mainly anti cholinergic effect, whereas at higher 
concentration it is totally a calcium antagonist action. Its side effects are 
hypotension, facial flushing, head ache, dizziness, constipation, rashes, 
weakness and palpitation. Because of cardiac toxicity it was withdrawn. A 
bladder specific calcium channel antagonist is not known to exist. 
3. POTASSIUM CHANNEL OPENER 
They efficiently relax various types of smooth muscles, including 
detrusor smooth muscle, by increasing potassium efflux, resulting in membrane 
hyperpolarisation. Pinacidil and cromokalim perhaps are found to be 200 times 
more potent as inhibitors of vascular preparations than  detrusor muscle.34 
4. PROSTAGLANDIN INHIBITORS 
It has a role in the excitatory neuro transmission to bladder and in the 
development of bladder contractility. There is a theoretical basis for the use of 
COX – 2 Inhibitors in OAB, but there is no objective evidence available at this 
time.  
5. β - ADRENERGIC AGONISTS – TERBUTALINE.    
The presence of β - adrenergic receptor in human bladder has promoted 
attempts to increase bladder capacity. Its stimulation cause no change in lung 
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capacity in normal human where as it does affect patients with bronchial 
asthma. 
It also produces palpitation, tachycardia and tremors. The ICI committee 
does not recommend this drug for the management of  OAB.35 
6. α - adrenergic antagonists 
These drugs have no significant role to decrease detrusor contractility or 
increase bladder capacity, because α - adrenergic antagonists have minimal  
contractile effects on human detrusor smooth muscle from normal individuals. 
However, the peripheral contribution of these receptors of the bladder get 
changed in neurological diseases or injury and  in bladder outlet obstruction. 
Parasympathetic decentralization has been reported to lead to a marked 
increase in adrenergic innervations of the bladder, with a resultant conversion 
of the usual beta (relaxant) response of the bladder in response to sympathetic 
stimulation to an alpha (contractile) effect. ICI committee judged the 
pharmacologic and physiologic evidence and they did not recommend it for 
OAB. 
7. Tricyclic anti depressants 
Tricyclic anti depressants such as imipramine are useful agents for 
facilitating urine storage. They act by decreasing bladder contractility and by 
increasing outlet resistance. They have central and peripheral anti – cholinergic 
effects. It is effective in the treatment of nocturnal enuresis in children.36 
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TOLTERODINE 
It is a new competitive muscarinic receptor antagonist with good clinical 
efficacy. It was one of the most frequently prescribed single agent for the 
treatment of OAB in USA. 
 
 
 
 
 
Structural formula of Tolterodine 
It is not receptor selective but at least in some experimental models, it 
showed selectivity for bladder tissue over salivary tissue37. 
Pharamacokinetics 38 
Absorption: It is rapidly absorbed from gastro intestinal tract. The 
bioavailability of tolterodine is approximately 86% and plasma concentrations 
of tolterodine are proportional to the dose administered. Its passage across 
blood brain barrier is restricted.  
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Metabolism: Tolterodine is extensively metabolized in the liver. The 
primary pathway for metabolism is by CYP2 D6. It is converted into an active 
metabolite, 5 hydroxy methyl tolterodine (5 – HM) that has 100% potency of 
toltrodine. Following an oral dose 4mg, the peak serum concentration of 5 HM, 
achieved is 5mg/mL. Variation in CYP2 D6 level do not affect the duration of 
action of drug. 
Excretion: It is excreted in the urine and feces.  
No significant gender difference is present in the kinetics of tolterodine. 
It is contraindicated in pregnancy and lactating mothers. It should be used with 
caution in hepatic impairment.  
Stahl and coworkers studied the effect of a single dose 6.4mg of 
tolterodine on bladder and salivary function. They found that the inhibitory 
effect on bladder function persisted upto 5 hours. But it was observed that the 
stimulated salivation was inhibited only around the time of peak serum levels. 
5 hours after administration of tolterodine, the effect on bladder was 
maintained, where as no significant effect on salivation could be detected39.   
In another study, Appell analysed a total of 1120 patients in whom the 
effect of tolterodine 1 or 2mg given twice daily was compared with immediate 
release oxybutynin 5mg given three times a day. It was found that both the 
drugs significantly reduced the OAB symptoms and increased the volume 
voided per void. There was no difference in efficacy between the 2 mg dose of 
tolterodine and the 5mg dose of oxybutynin. But tolerance was significantly 
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better with tolterodine. The adverse effects such as dry mouth leading to dose 
reduction and patient withdrawals were more with oxybutynin.  
In the year 2000, Chancellor and his colleagues reported that in a double 
blind study 40 where tolterodine 2mg twice daily was compared with placebo, 
the symptoms of OAB were significantly reduced from baseline in tolterodine 
group. But the incidence of severe and moderate dry mouth was 2% and 10% 
respectively with tolterodine as against 0% and 2% of placebo. The other 
adverse events such as constipation were also significantly high in the 
tolterodine group.  
SOLIFENACIN 
Solifenacin succinate is a muscarinic antagonist. Chemically, solifenacin 
succinate is butanedioic acid, compounded with (1S) – (3R) – 1 azabicyclol 
(2.2.2) oct-3 – yl3. 4-dihydro-1-phenyl-2 (1H) - isoquinolinecarboxylate (1;1) 
having an empirical formula of C23 H26 N2 O2 C4 H6 O4 41 
 
 
Structural formula of solifenacin succinate. 
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 Solifenacin is competitive muscarinic receptor antagonist. Muscarnic 
receptors play an important role in several major cholinergically mediated 
functions, including contractions of urinary bladder, smooth muscles and 
stimulation of salivary secretion. As we know that contraction of bladder is 
carried out by the release of acetylcholine from cholinergic nerves leading to 
stimulation of muscarinic receptors on the detrusor smooth muscle. 
Solifenacin acts as a direct antagonist at muscarinic acetylcholine 
receptors in cholinergically innervated organs. Its antiocholinergic-
parasympatholytic action reduces the tones of smooth muscle in the bladder, 
effectively reducing the number of required voids, urge incontinence episodes, 
urge severity and improving retention, facilitating increased volume per void. 
Pharamacokinetics: 
Absorption: After oral administration, peak plasma levels of 
Solifenacin are reached within 3-8 hours and at steady state ranged from 32.3 
to 62.9ng/ml for the 5 and 10mg solifenacin tablets respectively. The absolute 
bioavailability of solifenacin is approximately 90% and plasma concentrations 
of solifenacin are proportional to the dose administered. 
Effect of food: There is no significant effect of food on the 
pharmacokinetics of Solifenacin.42 
Distribution: Solifenacin is approximately 98% bound to human plasma 
proteins, principally to ∝1-acid glycoprotein. Solifenacin is highly distributed 
to non-CNS tissues.  
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Metabolism: Solifenacin is extensively metabolized in the liver. The 
primary pathway for elimination is by way of CYP3A4; however, alternate 
metabolic pathway exists. The primary metabolic routes of solifenacin are 
through N – oxidation of the quinuclidin ring and 4R – hydroxylation of 
tetrahydroisoquinoline ring. One pharmacologically active metabolite (4R –
hydroxy Solifenacin), occurring at low concentrations and unlikely to 
contribute significantly to clinical activity, and three pharmacologically 
inactive metabolites (N-glucuronide and the N-oxide and 4R hydroxyl-N-oxide 
of Solifenacin) have been found in human plasma after oral dosing. 
Excretion: It is excreted mainly in urine and feces. The major 
metabolites excreted in urine are N – oxide of solifenacin, 4R-hydroxy N-oxide 
of solifenacin, and in feces 4R-hydroxy solifenacin. The elimination half – life 
of solifenacin following chronic dosing is approximately 45-68 hours. 
Pharmacokinetics in special populations 
Age: Multiple dose studies of solifenacin in elderly volunteers (65-80 
years) showed that plasma half life values were 20-25% higher as compared to 
the younger volunteers (18-55 years). 
Pediatric population: The pharmacokinetics of solifenacin has not been 
established in pediatric patients. 
Gender: The pharmacokinetics of Solifenacin is not significantly 
influenced by gender. 
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Race: The number of subjects of different races studied are not adequate 
to make any conclusion on the effect of race on the pharamacokinetics of 
Solifenacin. 
Renal impairment: Solifenacin should be used with caution in patients 
with renal impairment. Doses of Solifenacin greater than 5mg are not 
recommended in patients with severe renal impairment. It is contraindicated in 
severe hepatic impairment. 
Pregnancy and Lactation 
There are no adequate and well-controlled studies in pregnant women, 
because animal reproduction studies are not always predictive of human 
response. The effect of solifenacin on labor and delivery in human has not been 
studied. After oral administration of solifenacin to lactating mice, radioactivity 
was detected in maternal milk. It is not known whether solifenacin is excreated 
in human milk. Because many drugs are excreted in human milk, solifenacin 
should not be administered during breast feeding. 
Drug – drug interaction: At therapeutic concentrations, solifenacin 
does not inhibit CYP 1A1/2, 2C9, 2C19, 2D6 or 3A4 derived from human liver 
microsomes. Inducers or inhibitors of CYP 3A4 may alter solifenacin 
pharmacokinetics. 
The administration of 10mg of Solifenacin, in the presence of 400mg of 
ketoconazole, a potent inhibitor of CYP3A4, the mean plasma concentration 
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maximum and AUC of solifenacin are increased by 1.5 and 2.7 – fold 
respectively.  
Therefore it is recommended not to exceed a 5mg of daily dose of 
Solifenacin when administerd with therapeutic doses of ketoconazole or other 
CYP 3A4 inhibitors. 
Oral contraceptives: There are no significant changes in the plasma 
concentration of combined oral contraceptives (ethynyl estradiol/levogestrel) 
when administered along with solifenacin. 
Warfarin: Solifenacin has no significant effect on the pharmacokinetics 
of R-warfarin or S-warfarin. 
Digoxin: Solifenacin has no significant effect on the pharmacokinetics 
of digoxin (0.125mg/day) in healthy subjects.  
Indications 
Solifenacin is indicated for the treatment of OAB with symptoms of 
urge urinary incontinence, urgency and urinary frequency. 
Contraindications 
It is contraindicated in patients with urinary retention, gastric retention, 
and uncontrolled narrow angle glaucoma and in patients who have 
demonstrated hypersensitivity to the drug. 
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Precautions 
 Bladder out flow obstruction 
 Gastrointestinal obstruction disorders and decreased GI motility 
 Controlled narrow – angle glaucoma 
 Reduced renal function 
 Reduced hepatic function. 
Geriatric use: The safety and effectiveness between older and younger 
patients treated with solifenacin is similar. 
Adverse reactions 
Expected side effects of anti muscarinic agents are dry mouth, 
constipation, blurred vision (accommodation abnormalities), urinary retention 
and dry eyes. The most common adverse events reported in patients treated 
with solifenacin were dry mouth and constipation and the incidence of these 
side effects was higher in the 10mg compared to the 5mg group. 
Dosage and Administration 
The recommended dose of Solifenacin is 5mg once daily.  
 30 
The tolerability of Solifenacin was assessed in single dose and multiple 
dose studies conducted at Netherland Europe in 200343. The single dose study 
was a dose escalating study in which the patients were asked to take only one 
dose of solifenacin 5, 10, 20, 30, 40, 60, 80 and100 mg. They were advised to 
return for post study visit 10-17 days after dosing. In the multiple doses study   
the patients were given Solifenacin 5, 10, 20 & 30 mg   once daily for 28 
consecutive days. The incidence of adverse events were analysed and was 
found that the adverse events were more in multiple dose studies than single 
dose studies and there was a dose dependant increase in the incidence of 
adverse events. The incidence of adverse events with 5 mg solifenacin given 
for 28 days was 62.5%. There were no cases of dry mouth (0%), but 37.5% the 
patients suffered from blurred vision and 12.5% patients had headache & 
somnolence.  
In another study conducted Sheffield, United Kingdom 2003, a total of 
225 patients aged between 21 to 83 years, with OAB were randomized to 
receive solifenacin or tolterodine or placebo. 85% of the subjects [192 patients] 
completed the study.44   Patients received once daily doses of solifenacin 2.5, 5, 
10 and 20mg or tolterodine 2mg twice daily or placebo for 28 days. The results 
were analyzed after 2 weeks. 
It was observed that the frequency of micturition reduction occurred 
rapidly with 2.5, 5, 10, and 20mg/day dosages of solifenacin compared with 
placebo. It was significant for 5 & 10mg and highly significant for 20mg. 
Though tolterodine was superior to placebo, solifenacin produced better results 
when compared with tolteradine. The other parameter, volume voided per void 
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showed statistically significantly increase from baseline to study end point with 
solifenacin group, when compared with placebo and tolterodine.  
5 mg solifanacin was found to be as effective as higher doses of 
solifenacin (10 & 20 mg). 5 mg solifenacin resulted in 18% reduction of 
number of micturition episodes in 24 hrs, 28% improvement in mean volume 
voided per void and 42% reduction in urgency episodes.  
In an international multicentre randomized, double blind study 
conducted at New Jersey, USA, 200345  of 12  weeks duration, solifenacin was 
compared with tolterodine and placebo. In this study, adult patients with 
symptoms of OAB were treated with solifenacin 5mg or 10mg once daily, 
tolterodine 2mg twice daily and placebo. 1281 patients were enrolled and 1033 
patients completed the study. Both solifenacin and tolterodine were observed to 
be significantly superior to placebo. But the reduction of mean number of 
micturition/24 hours, reduction of mean number of urgency episodes (5 mg 
solifenacin – 51.9%, 2 mg tolterodine – 37.9%) and reduction in the number of 
incontinence episodes were significantly in favor of solifenacin than 
tolterodine.  
STAR trial Brimingham, UK, 2005 conducted in patients with OAB 
published in 2005 reported a comparative evaluation of efficacy and tolerability 
of solifenacin and extended release tolteradine in treating OAB. This was a 
prospective, double blind, double dummy, parallel group, 12 week study, 
conducted with 5 & 10 mg of solifenacin and tolterodine extended release 
tablet 4 mg. It was concluded that solifenacin was superior to tolteradine ER 
with respect to majority of the efficacy variables. They analised the efficacy 
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variables such as urgency episodes, incontinence episodes, urge incontinence 
and pad usage. In this study 50% reduction in incontinence episodes was 
observed. The majority of side effects were mild to moderate in nature and 
discontinuations were low and comparable in both solifenacin & tolterodine 
groups. 46 
Tolterodine has been tested in patients for a duration ranging from 2 to 
12 weeks. But it was observed that after 2 weeks of treatment, a dose – related 
improvement in micturition variables was observed. The difference was 
significant for urgency, frequency of micturition and average volume voided 
per micturition.47 
In different studies conducted with solifenacin, effect of solifenacin on 
micturiton variables was evaluated after 4 weeks and 12 weeks of therapy. It 
was observed that maximum effect was evident as early as in 4 weeks.44 
This study is planned to evaluate the efficacy and tolerability of 
solifenacin 5 mg once daily in comparison with tolterodine 2 mg twice daily in 
30 patients with OAB. Since the antimuscarinic effect of tolterodine and 
solifencain becomes evident by 2 to 4 weeks of therapy, the duration of this 
study was limited for 4 weeks.  
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STUDY OBJECTIVES 
• To compare the efficacy of solifenacin (5 mg once daily) and 
tolterodine (2 mg twice daily) in reducing the number of micturitions 
per day (24hours), number of incontinence episodes, urgency 
episodes in patients with over active bladder (OAB). 
• To compare the efficacy of solifenacin and tolterodine on volume 
voided per void in patients with OAB. 
• To evaluate the tolerability of solifenacin and tolterodine in OAB.  
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MATERIALS AND METHODS 
Study center    
Department of Urology, Government General Hospital and     
Department of Urology, Kasturba Gandhi Government Hospital for Women & 
Children, Madras Medical College, Chennai. 
Study design 
Open label, comparative, randomized, parallel group, prospective study. 
Study duration 
4 weeks. 
Study period 
01-05-05   to   15-06-2006 
Study sample 
30 patients 
Inclusion Criteria 
1. Age between 18 to 75 years. 
2. Sex: both  males & female. 
3. Urine culture should be negative for microorganisms. 
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4. Patients with overactive bladder must have experienced frequency of 
micturition on an average of >8 times per 24hours and >3episodes of 
urgency or incontinency during the 3 days, immediately prior to 
randomization. 
Exclusion criteria 
1. Patients with 
 History of hypersensitivity to the study drugs solifenacin & tolterodine 
and other anticholinergic drugs.  
 History of stress incontinence, urinary outflow obstruction recurrent or 
symptomatic urinary tract infection, interstitial cystitis, uninvestigated 
haematuria or haematuria due to malignant disease. 
 Presence of neurological cause for detrusor muscle over activity. 
 Any condition in which the use of anti muscarinic therapy is 
contraindicated. such as patients with urinary retention, gastric retention 
or uncontrolled  narrow- angle glaucoma. 
 An indwelling catheter or use of intermittent catheterization. 
 QT interval prolongation in ECG 
 Significant hepatic, cardiac, renal, hematological, neurological,                    
psychiatric or endocrinological disorder. 
 History of Diabetes mellitus, hypertension and tuberculosis. 
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2. Patients who have 
 Received previous pelvic irradiation or currently have malignant 
diseases of the pelvic organ. 
 Received treatment with any anti muscarinic drug or any  drug for   
urinary incontinence or any non- pharmacological treatment for over 
active bladder including electro- stimulation or bladder training 
within two weeks before the study. 
 Taken part in any other investigational study in the last one-month 
prior to enrollment. 
3. Urine culture positive growth for microorganisms. 
4. Pregnant or breast-feeding woman or woman of child bearing potential 
not using a   reliable method of contraception. 
Study procedure 
The study was conducted after obtaining approval from the Institutional 
Ethical Committee (IEC). All study related procedures in a patient were 
initiated only after obtaining written informed consent. Patients attending out- 
patient department of Urology in Government General Hospital and Kasturba 
Gandhi Government Hospital for Women& Children, Chennai, with   
symptoms   of   over   active    bladder [Increased frequency of micturition 
more than 8 times per day and more than   3 episodes of urgency, with or 
without urge incontinence and nocturia in three days consecutive days] were 
explained about the study purpose and procedures. 
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Screening 
Written informed consent was obtained from those who were willing to 
participate in the study. The patients were enrolled   and a screening 
identification number was assigned to each patient. The demographic data, 
contact number and address were recorded. They were screened by medical 
history, physical examination and laboratory investigations like, urine routine 
analysis, mid stream urine for microbial culture.  Blood sample for 
haematalogical and biochemical analysis was collected. X-Ray chest and ECG 
were also taken.  
A voiding diary card was issued to each patients and they had to 
undergo a 3 days run in- phase during which they were instructed to record the 
following details in the voiding diary card for 3 consecutive days. 
1. Voiding frequency [number of times patients passing urine in 24/hours] 
2. Number of urgency episodes [number of times in a day where there is a 
strong  need  to go   to the toilet right away] 
3. Urge incontinence episodes [number of leaking/wetting episodes in a 
day] 
4. Incidence of nocturia [number of times the patients had to wake up at 
night to pass urine] 
5. Volume of urine passed per void [one liter plastic measuring jar was 
provided to each patient and they were instructed to collect and measure 
the volume of urine passed per void and enter it in the voiding diary 
card] 
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They were asked to report to the out patient department after three days 
with the completed voiding diary card.  
Baseline [0-day] 
      The voiding diary card and laboratory results were reviewed for the 63 
patients screened, 10 patients were found to have diabetes mellitus and 23 
patients urine culture showed positive for microorganisms. The remaining 30 
patients those who fulfilled the inclusion and exclusion criteria   were recruited 
for the study and a separate study number was assigned. The voiding diary card 
and the laboratory results were collected. 
Baseline clinical assessment of urinary symptoms as entered in the 
voiding diary card and subjective assessments of problems associated with 
bladder   symptoms were recorded. They were then randomized to receive 
either solifenacin or tolterodine.  
 Solifenacin 5mg once daily to be taken with or without food for   4weeks 
Tolterodine 2mg   twice daily to be taken with or without food for 4weeks. 
• Drugs were issued   for   2 weeks only. They were asked to report to 
the out patient department at the end of 2 weeks. 
• In the four weeks study, patients had to make two follow up visits to 
the out patient department once in 14 days.  
• If any adverse effect was observed, the patients were instructed to 
contact the physician immediately over telephone or to attend the out 
patient department at any point of the study.  
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• A new voiding diary card was issued and the patients were instructed 
to enter the micturition symptoms on the 12th, 13th and 14th day of each 
follow up visit.     
• Medication compliance card was also issued to each   patient to 
check the regularity of drug therapy and   they were instructed to 
enter the dates of medication taken. The patients were reminded by 
post /telephone regarding the filling of   the   voiding diary card and 
the follow-up visit date. 
Followup-1 
After 14 days the study participants were instructed to report to the 
outpatient department along with the filled voiding diary card, medication 
compliance card and   empty medication pack, which were collected. Adverse 
effect if any reported was recorded. A new medication compliance card, 
voiding diary card and medication for the subsequent 2 weeks were issued and 
were instructed to follow the same procedure as done before. 
Followup-2 
At the end of 28th day, the voiding diary card, drug compliance card and. 
empty medication packs were collected.  Adverse effect if any was recorded. 
Routine clinical examination, clinical assessment about urinary symptoms, 
subjective assessments of problems associated with bladder symptoms were   
recorded and compliance with medication were assessed at the end  of 14th day 
and 28th day. 
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Global assessment of over all efficacy and tolerability by patient and 
urologist was recorded. Complete Haemogram, blood biochemistry and urine 
routine analysis were done at the end of the study.  
Clinical assessment was based on the urinary symptoms which were 
recorded in the voiding diary. The improvement in urinary symptoms was 
decided based on the following efficacy variables, the reduction in the number 
of micturition per 24 hours, number of incontinence episodes, urgency 
episodes, volume of urine voided and nocturia.  
The subjective assessment of problems associated with bladder 
symptoms  consists of 6 point Likert scale 
0- No problem 
1- Very minor problem 
2- Minor problem 
3- Moderate problem 
4- Severe problem 
5- Many severe problem 
 Post treatment improvement in symptoms was assessed by the 
betterment in the score scale.  
 Global assessmentof efficacy and tolerability was done by the patient 
and the urologist at the end of study. 
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Global assessment by patient and urologist for over all efficacy 
Patient                       Urologist  
0 - Very good 0 - Very good 
1 - Good  1 - Good 
2 - Satisfactory 2 - Satisfactory 
3 -   Poor  3 - Poor 
Global assessment by patient and urologist for over all tolerability 
Patient  Urologist  
0 - Very good 0 - Very good 
1 - Good  1 - Good 
2 - Satisfactory 2 - Satisfactory 
3 -   Poor  3 - Poor 
At the end of the study Global assessment of efficacy and tolerability of 
solifenacin and tolterodine were done by the patient and urologist. 
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LABORATORY  ASSESSMENT 
The following laboratory parameters were done 
1. Haemogram 
 Haemoglobulin [Hb%], platelet count, Total count, Differential count. 
2. Blood chemistry 
Blood sugar 
Blood urea 
Serum Creatinine 
Total bilirubin 
Serum glutamic oxaloacetic transaminase [SGOT] 
Serum glutamic pyruvate transaminase [SGPT] 
3. Urinalysis 
Urine routine   albumin, sugar, deposits 
Urine culture for microorganism. 
4. X- Ray chest 
5. ECG 
 1, 2, 3, were done at screening & at the end of 28 days. 
4, 5, were done at screening only  
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Lab parameters were concidered to be abnormal as shown below 
Hb% decrease by 5% difference- significant. 
TC increase/ decrease by 5% difference- significant. 
Serum creatinine increase by 5% difference- significant. 
Glucose increase/decrease by 20%- significant 
Bilirubin increase by1.5 times- significant 
SGOT/SGPT increase by1.5 times- significant. 
The results were analyzed statistically.   
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RESULTS 
Sixty Three patients were screened for their eligibility to participate in 
the study. Among them, 30 patients who fulfilled the inclusion criteria were 
enrolled for the study, in which there were 4 males and 26 females. All the 
patients completed the study. There were no dropouts in either group.  
 
The following tests were used for statistical analysis of data. 
• Paired t test –to compare the base line data with end point data of 
efficacy variables and laboratory parameters of each group 
• Two sample t test – to compare the end point data of solifenacin and 
tolterodine  
• Chi square test – to compare the global assessment of efficacy and 
tolerability of solifenac in and tolteradine.
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Table-1 Shows  the statistical value of average number of micturition 
- Values are mean ± SEM 
-  The reduction from the base line to end point was statistically significant 
for both soliteracin and tolterodine.[ p<0.001] 
- The reduction in the average number of micturition at the end of the 
study in both solifenacin group and tolterodine group was compared. It 
was statistically significant for solifenacin (p < 0.05). 
Figure-3 Shows the graphical representation of average number of                        
micturition between two drugs 
- The  average no of micturition  by the drug solifenacin reduced from 
13.07 at base line to 6.2 at the end of 28 days [end point].  
- The  average no of micturition by the drug tolterodine reduced from 
12.27 at base line to 7.53 at the end of 28 days [end point].    
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Table-2. Shows the statistical value of urgency episodes 
- Values are mean ± SEM  
-  The reduction from the base line to end point was statistically significant 
for both soliteracin and tolterodine.[ p<0.001] 
- The reduction in the average number of urgency at the end of the study 
in both solifenacin group and tolterodine group was compared. It was 
statistically significant for solifenacin (p < 0.05). 
Figure-4 Shows the graphical representation of urgency                                 
episodes  between two  drugs 
- The reduction of mean no of urgency episodes by the drug  
solifenacin from base line 6.67 to 1.6 at 28 days [end point]. was 
represented in the graph. 
- The reduction of mean no of urgency episodes by the drug 
tolterodine from base line 6  to 2.07 at28 days [end point]. was 
marked in the graph.  
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Table-3 Shows  the statistical value of mean number of incontinence 
- Values are mean ± SEM 
-  The reduction from the base line to end point was statistically significant 
for both soliteracin and tolterodine.[ p<0.001] 
- The reduction in the average number of incontinence at the end of the 
study in both solifenacin group and tolterodine group was compared. It 
was statistically significant for solifenacin (p < 0.05). 
Figure-5 Shows the graphical representation of mean number of 
Incontinence  between two  drugs 
- The reduction of mean no of incontinence episodes by the drug 
solifenacin from base line to 28 days [end point] 1.8 to 0.13 is  
represented   in  the graph. 
- The reduction of mean no of incontinence episodes by the drug  
tolterodine from base line to 28 days [end point] 2.23 to 0.43 was shown 
in the graph.  
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Table-4 Shows  the statistical value of mean number of volume voided 
- Values are mean ± SEM 
- The increased mean volume voided from base line to 28 days [end 
point] was significant for  both the drugs [P<0.001]. 
- The increase of volume voided at the end point of both drugs was 
compared  it was statistically significant for solifenancin (P<0.05). 
Figure-6 Shows the graphical representation of mean number                                    
of volume voided between two  drugs 
- The increase in mean  volume voided  by the drug solifenacin from 
base line to 28 days [end point] was 168ml to 268ml  represented in  
the graph. 
- The increase in volume of urine voided  by the drug tolterodine from 
base line to 28 days [end point] was 157ml to217ml represented in  
the graph.  
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Table-5 Shows the statistical value of nocturia 
- Values are mean ± SEM 
- The reduction of nocturia from base line to 28days[ end point]  was 
significant for  both the drugs.[ p<0.001]. 
- The reduction of nocturia at the end point for solifenacin was significant 
when compared with the tolterodine end point value (P<0.05). 
Figure-7 Shows the graphical representation of mean number                                    
of nocturia between two  drugs 
- The reduction of  mean no of nocturia by the drug solifenacin from  
base line to 28 days [end point]  was 5.4 to 0.87, which is shown  in 
the graph. 
- The reduction of  mean no of  nocturia by the drug  tolterodine from 
base line to 28 days [end point] was 4.67 to 1.07, which is shown in 
the graph.  
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Table-6. Shows the statistical analysis of global efficacy assessment by 
patient and urologist 
• The efficacy analysis of reduction in urinary symptoms from baseline to 
28 days [end point]. The percentage was better in solifenacin groups.  
Figure-8 Shows the graphical representation of global efficacy assessment 
by patient and urologist 
• The efficacy analysis of urinary symptoms by patients and urologist was 
represented in the graph for both the drugs. 
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Table-7. Shows the statistical analysis of global tolerability assessment  by 
patient and urologist 
• In tolerability analysis the percentage of tolerability to drug solifenacin 
is more than the drug tolterodine. 
Fig-9: Shows the graphical representation of tolerability of both the drugs by 
patients and urologist. 
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ADVERSE EVENTS 
No adverse events were experienced in the solifenacin group. Where as 
5 patients (33.3%) in the tolterodine group experienced dry ness of mouth 
which did not require discontinuation of therapy. 
ASSESSMENT OF COMPLIANCE 
The compliance was assessed at the end of 2 weeks and 4 weeks. In this 
study all the 15 patients in solifenacin group and 15 in tolterodine group had 
taken all the prescribed medications as per schedule. The compliance was 
assessed by reviewing the compliance assessment diary card and by checking 
the medication container.  
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DISCUSSION 
OAB is more prevalent in older age groups and more common in 
women. Generally anticholinergics are useful in OAB. But atropine was rarely 
used to treat this condition due to its systemic side effects. The clinical utility 
of available antimuscarinic agents is limited because of their lack of bladder 
specific action. 
Propantheline bromide was first used in OAB, but it has systemic 
antimuscarinic action which approximates atropine. Oxybutynin a M1 & M3 
receptor blocker was in use for more than 20 yrs. Having high affinity for 
parotid gland than bladder, its use is also on decline.  
Tolterodine, a non selective muscarinic blocker shows selectivity to 
bladder with antimuscarinic side effects. Then Darifenacin which is said to be 
uro selective but still in impairs salivary flow. Solifenacin is a new drug having 
high potency and bladder specific muscarinic (M3) blocking property with 
minimal side effects.  
There were only few foreign studies which described the comparative 
efficacy of tolteroadine and solifenacin in OAB. No study was done with these 
two drugs in India to evaluate the efficacy and safety in OAB.  
Institute of Pharmacology, Madras Medical College, Chennai in 
collaboration with Dept. of Urology, Government General Hospital, Chennai 
and Department of Urology, Kasturba Gandhi Government Hospital for 
 54 
Women & Children, Madras Medical College, Chennai has undertaken the 
study to compare the efficacy and tolerability of solifenacin and tolerodine in 
OAB. 
In our study 30 patients with the clinical features of OAB were included. 
They were treated with either solifenacin 5 mg /day or tolterodine 2 mg twice 
daily for 4 weeks.  
The efficacy variables such as, reduction in the number of micturition 
per 24 hours, number of incontinence episodes, urgency episodes, volume of 
urine voided and nocturia were recorded during baseline and at the end of the 
study (after 28 days) was analysed statistically. Global assessment of efficacy 
and tolerability by both patient and urologist was done at the end of the study. 
Adverse events, it reported or observed were recorded. 
Symptoms of OAB  
In our study frequency of  micturition which is a very trouble some 
symptom of OAB was reduced. When comparing baseline to the end point with 
in the groups, there was a statistically significant reduction in frequency of 
micturition (p < 0.001). On comparing end point value of solifenacin and 
tolerodine groups, there was a statistically significant reduction in solifenacin 
group (P < 0.05). The percentage reduction in the frequency of micturition with 
solifenancin 5 mg once day was 51.89% but with tolterodine 2 mg twice a day 
it was 36.88%. But in a study conducted in sheffield united kingdom 2003 the 
percentage reduction was 18% with solifenancin 5 mg od.44 
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In our study Urgency episodes were reduced in both the groups. When 
comparing the base line to the end point within the groups, there was a 
statistically significant reduction in urgency of micturition (P < 0.001). On 
comparing the end point value of solifenacin and tolterodine groups, there was 
a statistically significant reduction in soliferacin group (P <0.05). The 
percentage reduction in urgency episodes in our study was 79.29% for 
solifenancin and 63.09% for tolterodine. But in a study conducted in New Jursy 
USA, 200345, it was observed that reduction in urgency episodus for 
soliferancin 4 mg was 51.9% and 37.9% for tolterodine.  
The Incontinence episodes reduced in both the trial drugs during our 
study (P < 0.001) in comparing the baseline to end point values with in the 
groups. In comparing the end point value of solifenacin and tolterodine, 
solifenacin was statistically significant (P <0.05) than tolterodine. In Star Trial 
conducted in Brimingham, UK 200546, it was  reported that the percentage of 
reduction in continence episodes from baseline to the end of the study was 50% 
with soliferacin 5 mg. But in our study the reduction in incontinence episodes 
was 96.26% with solifenancin 5 mg and 84.6%  for tolterodine 2 mg. 
In our study both the drugs reduced the frequency of micturition, and the 
volume voided per void was increased by these drugs significantly (p < 
0.001). In comparing end point of the two drugs the effect of solifenacin was 
more significant (p < 0.05). In our study percentage improvement for 
soliferacin 5 mg was 61.67% and for talterodine it was 42.27%. 
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Nocturia was reduced in both groups in this study. Nocturia reduction 
also shows the same results (P < 0.001). In between end point of two drugs 
solifenacin was better (P < 0.05). 
Efficacy analysis by the patient showed solifenacin to be better than 
tolterodine. Of the 15 patients in solifenacin group 2(13.3%) assessed  the 
therapy to be ‘very good’, 11(73.4%) patients attributed the efficacy to be 
‘good’ and two patients 13.3%  were satisfied. Where as in tolterodine group 
none of the patients claimed the therapy to be very good, 7(46.7%) patients 
responded with the reply ‘good’ and the rest ‘satisfactory 53.5%. Statistical 
analysis also stand soliferacin to be better than tolterodine, (p < 0.05). 
The efficacy analysis by the urologist also showed solifenacin to be a 
better drug in OAB. According to the assessment by urologist solifenacin 
produced ‘very good’ results in 2 patients (13.3%) and the rest were ‘good’ 
(86.7%) responder. The effect of tolterodine was good in 10 patients 66.7% and 
satisfactory in 5 patients. 33.3% Onanalysis statistically solifenacin was better 
than tolterodine (P < 0.05). 
The over all efficacy assessment  by the patient and the urologist were in 
favour of solifenacin. 
Tolerability was also better for solifenacin than tolterodine, when 
assessed by patients and urologist. 
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Adverse effects: 
In our study solifenacin group experienced no adverse effect, where as 
tolterodine group 5 patients reported dryness of mouth (33.3%) which did not 
require discontinuation of therapy.  
In a study conducted at Ntherland Europe 200343  5 mg soliofenacin 
resulted in 37.5% of blurred vision and 12.5% of head ache & somnolence. But 
in our study there was no adverse event with solifenacin 5 mg.43  
Laboratory parameters 
There was no statistically significant change in the laboratory 
parameters, when comparing baseline and end point values with in the groups. 
 The results of our study were well in accordance with the studies 
conducted abroad. Solifenacin produced better control of symptoms in over 
active bladder and was well tolerated. 
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CONCLUSION 
From our study we conclude that solifenacin 5mg once daily is effective 
and well tolerated than tolterodine 2mg twice a day in the management of over 
active bladder by  
* Reducing the number of micturitions per day (24 hours), number 
of incontinence episodes, urgency episodes.  
* More effective in increasing the volume voided per void.  
* Better tolerance.  
 
 Table - 1: Average number of micturition episodes 
 
 
Number of micturition 
episodes 
Solifenacin 
(n=15) 
Tolterodine 
(n=15) 
Solifenacin Vs 
Tolterodine (end 
point analysis) 
Baseline 13.07 ± 2.99 12.27 ± 2.09 
End point (28 days) 6.20 ± 1.32 7.53 ± 1.46 
% change over from baseline  51.89 ± 8.26 36.88 ± 16.03 
Statistical test and 
significance level 
Paired t test 
p < 0.001 
Paired t test 
p < 0.001 
Two sample t test 
P <0. 05 
 
                      
13.07
6.2
12.27
7.53
0
2
4
6
8
10
12
14
N
o
.
 
o
f m
ic
tu
rit
io
n
Solifenacin Tolterodine
AVERAGE NUMBER OF MICTURITION
Baseline
28 days
 
Fig-3 is graphical representation of table-1 
Table-2: Mean number of urgency episodes 
Number  of urgency 
episodes 
Solifenacin 
[n=15] 
Tolterodine 
[n=15] 
Solifenacin Vs 
Tolterodine (end 
point analysis) 
Baseline 6.67 ± 3.56 6.00 ± 2.55 
End point (28 days) 1.60 ± 1.68 2.07 ± 0.88 
% change over from baseline  78.29 ± 16.51 63.09 ± 14.09 
Statistical test and 
significance level 
Paired t test 
p < 0.001 
Paired t test 
p < 0.001 
 
Two sample t test 
P <0.05 
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Fig-4 is the graphical representation of table-2 
Table - 3: Mean number of incontinence episodes 
Mean number of incontinence Solifenacin [n=15] 
Tolterodine 
[n=15] 
Solifenacin Vs 
Tolterodine 
(end point 
analysis) 
Baseline 1.80 ± 2.27 2.23 ± 1.68 
End point (28 days) 0.13 ± 0.52 0.43 ± 0.74 
% change over from baseline  96.26 ± 8.43 84.61 ± 18.67 
Statistical test and significance 
level 
Paired t test 
p < 0.001 
Paired t test 
p < 0.001 
Two sample t 
test 
P < 0.05 
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Fig-5 is graphical representation of table-3 
Table - 4:  Mean number of volume voided per void  
Mean number of volume 
voided 
Solifenacin 
[n=15] 
Toltreodine 
[n=15] 
Solifenacin Vs 
Tolterodine 
(end point 
analysis) 
Baseline 168.87 ± 50.45 157.07 ± 39.58 
End Point (28 days) 268.87 ± 83.76 217.16 ± 32.88 
% change over from baseline  61.67 ± 31.27 42.27 ± 22.55 
Statistical test and significance 
level 
Paired t test 
p < 0.001 
Paired t test 
p < 0.001 
Two sample t 
test 
P< 0.05 
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Fig-6 is graphical representation of table-4 
Table-5 Mean number of nocturia episodes 
Number of nocturia 
episodes Solifenacin Tolterodine 
Solifenacin Vs 
Tolterodine 
(end point 
analysis) 
Baseline 5.40 ± 4.31 4.67 ± 3.31 
End Point (28 days) 0.87 ± 1.24 1.07 ± 1.10 
% change over from baseline  89 .52 ± 11.89 80.05 ± 13.28 
Statistical test and 
significance level 
Paired t test 
p < 0.001 
Paired t test 
p < 0.001 
Two sample t 
test 
P < 0.05 
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Fig-7 is graphical representation of table-5 
Table -6: Global efficacy assessment 
Groups 
Solifenacin Tolterodine Efficacy assessment 
N % N % 
χ
2 
test 
Very good 2 13.3% 0 0% 
Good 11 73.4% 7 46.7% 
 
Patient 
Satisfactory 2 13.3% 8 53.3% 
 
   
 P = 0.05 
Very good 2 13.3% 0 0% 
Good 13 86.7% 10 66.7% 
Doctor 
Satisfactory 0 0% 5 33.3.7% 
 
    
P < 0.05 
 
 
 
 
 
 
 
 
 
 
 
Fig-8 is graphical representation of table-6
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TABLE - 7:  Global tolerability assessment 
Groups 
Solifenacin Tolterodine Tolerability 
N % N % 
χ
2 
test  
Very good 1 6.7% 0 0% 
Good 14 93.3% 15 100% 
Satisfactory 0 0% 0 0% 
Patient 
Poor 0 0% 0 0% 
 
   
 P < 0.05 
Very good 3 20.0% 1 6.7% 
Good 12 80.0% 14 93.3% 
Satisfactory 0 0% 0 0% 
Doctor 
Poor 0 0% 0 0% 
 
    
P < 0.05 
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Fig-9 is graphical representation of table-7 
 Table - 1: Average number of micturition episodes 
 
 
Number of micturition 
episodes 
Solifenacin 
(n=15) 
Tolerodine 
(n=15) 
Solifenacin Vs 
Tolterodine (end 
point analysis) 
Baseline 13.07 ± 2.99 12.27 ± 2.09 
End point (28 days) 6.20 ± 1.32 7.53 ± 1.46 
% change over from baseline  51.89 ± 8.26 36.88 ± 16.03 
Statistical test and 
significance level 
Paired t test 
p < 0.001 
Paired t test 
p < 0.001 
Two sample t test 
P <0.005 
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Fig-1 is graphical representation of table-1 
Table-2: Mean number of urgency episodes 
Number  of urgency 
episodes 
Solifenacin 
[n=15] 
Tolterodine 
[n=15] 
Solifenacin Vs 
Tolterodine (end 
point analysis) 
Baseline 6.67 ± 3.56 6.00 ± 2.55 
End point (28 days) 1.60 ± 1.68 2.07 ± 0.88 
% change over from baseline  78.29 ± 16.51 63.09 ± 14.09 
Statistical test and 
significance level 
Paired t test 
p < 0.001 
Paired t test 
p < 0.001 
 
Two sample t test 
P <0.005 
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Figure-2 is the graphical representation of table-2 
Table - 3: Mean number of incontinence episodes 
Mean number of incontinence Solifenacin [n=15] 
Tolterodine 
[n=15] 
Solifenacin Vs 
Tolterodine 
(end point 
analysis) 
Baseline 1.80 ± 2.27 2.23 ± 1.68 
End point (28 days) 0.13 ± 0.52 0.43 ± 0.74 
% change over from baseline  96.26 ± 8.43 84.61 ± 18.67 
Statistical test and significance 
level 
Paired t test 
p < 0.001 
Paired t test 
p < 0.001 
Two sample t 
test 
P < 0.05 
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Fig-3 is graphical representation of table-3 
Table - 4:  Mean number of volume voided per void  
Mean number of volume 
voided 
Solifenacin 
[n=15] 
Toltreodine 
[n=15] 
Solifenacin Vs 
Tolterodine 
(end point 
analysis) 
Baseline 168.87 ± 50.45 157.07 ± 39.58 
End Point (28 days) 268.87 ± 83.76 217.16 ± 32.88 
% change over from baseline  61.67 ± 31.27 42.27 ± 22.55 
Statistical test and significance 
level 
Paired t test 
p < 0.001 
Paired t test 
p < 0.001 
Two sample t 
test 
P< 0.03 
 
                 
MEAN VOLUME VOIDED
TolterodineSolifenacin
m
ea
n 
vo
lum
e 
vo
ide
d
400
300
200
100
0
Baseline
28 days
 
                           Fig-4 is graphical representation of table-4 
Table-5 Mean number of nocturia episodes 
Number of nocturia 
episodes Solifenacin Tolterodine 
Solifenacin Vs 
Tolterodine 
(end point 
analysis) 
Baseline 5.40 ± 4.31 4.67 ± 3.31 
End Point (28 days) 0.87 ± 1.24 1.07 ± 1.10 
% change over from baseline  89 .52 ± 11.89 80.05 ± 13.28 
Statistical test and 
significance level 
Paired t test 
p < 0.001 
Paired t test 
p < 0.001 
Two sample t 
test 
P < 0.05 
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Fig-5 is graphical representation of table-5 
Table -6: Global efficacy assessment 
Groups 
Solifenacin Tolterodine Efficacy assessment 
N % N % 
χ
2 
test 
Very good 2 13.3% 0 0% 
Good 11 73.4% 7 46.7% 
 
Patient 
Satisfactory 2 13.3% 8 53.3% 
 
   
 P = 0.04 
Very good 2 13.3% 0 0% 
     
Good 13 86.7% 10 66.7% 
Doctor 
Satisfactory 0 0% 5 33.3.7% 
 
    
P < 0.05 
 
 
 
 
 
 
 
 
 
 
 
Fig-6 is graphical representation of table-6
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TABLE - 7:  Global tolerability assessment 
Groups 
Solifenacin Tolterodine Tolerability 
N % N % 
χ
2 
test  
Very good 1 6.7% 0 0% 
Good 14 93.3% 15 100% 
Satisfactory 0 0% 0 0% 
Patient 
Poor 0 0% 0 0% 
 
   
 P < 0.05 
Very good 3 20.0% 1 6.7% 
Good 12 80.0% 14 93.3% 
Satisfactory 0 0% 0 0% 
Doctor 
Poor 0 0% 0 0% 
 
    
P < 0.05 
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Fig-7 is graphical representation of table-7 
